Second Sight’s next-gen “bionic eye” could reach US soon after FDA panel thumbs up
This article was originally published in Clinica
Executive Summary
An FDA panel has backed Second Sight’s Argus II retinal prosthesis system; if approved, as expected, it will become the first therapy in the US for patients with blindness due to retinitis pigmentosa (RP).